

Pam3Cys-SK4
C15H31
Ser-Lys-Lys-Lys-Lys
15 CH2 groups
U-Pam-14
14 CH2 + 1 NH
U-Pam-12
12 CH2 + 1 NH

Fig. 1



TentaGel S RAM
Solid phase synthesis
1
Fmoc-Pam2Cys-OH
PyBOP/DIPEA
NMP/DCM
2
1. piperidine, NMP
2. R-N=C=O
3 R = C14H29
4 R = C12H25
TFA
5 R = C14H29 (Upam-14)
6 R = C12H25 (Upam-12)

Fig.2 1



A
specific IL8 production
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Pam3CSK4
uPam12
uPam14
1000
200
40
8
1.6
0.32
nM
B
specific IL12 production
0.0
0.3
0.6
0.9
1.2
1.5
1.8
Pam3CysSK4
uPam-12
uPam-14
20
10
5
2.5
1.25
0.6
0.3
0.15
0.075
nM

Fig. 3





Activation marker upregulation on mouse DCs
Mean fluorescence intensity
400
350
300
250
200
150
100
50
0
CD40
CD86
Class II
Pam3CSK4
uPam14
unstimulated

Fig 4

A


IL12p40 production by moDC
specific IL12p40 production (ng/ml)
0
2
4
6
8
2 uM
500 nM
125 nM
Pam3CSK4
uPam14
Pam-SLP conjugate
uPam14-SLP conjugate

B


IL12p70 production by moDC
specific IL12p70 production (ng/ml)
0
50
100
150
2 uM
500 nM
125 nM
Pam3CSK4
uPam14
Pam-SLP conjugate
uPam14-SLP conjugate

C




CD86 expression on moDCs
Mean fluorescence intensity (MFI)
0
50
100
150
200
2 uM
500 nM
125 nM
Pam3CSK4
uPam14
Pam-SLP conjugate
uPam14-SLP conjugate
unstimulated

Fig 5

A


T-cell priming by uPam-conjugates;
ex-vivo IFNγ response
% IFNγ-producing CD8
0.3
0.2
0.1
0.0
uPam-SLP 5nmol
Pam-SLP 5 nmol
uPam / SLP mixture
Pam / SLP mixture
Naive

B



T-cell priming of specific CD8 T-cells by
uPam-conjugates
% tetramer+ of total CD8
20
15
10
5
0
uPam-SLP 5 nmol
Pam-SLP 5 nmol
uP am / SLP mixture
Pam / SLP mixture
Naive

Fig 6